AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15676050
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl 200 microg
Trial: 12593177
Drug: Inhaled long-acting
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled long-acting beta 2-mimetics and steroids
Trial: 10511331
Drug: Severe protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe protein restriction diet (0.30 g/kg/day) supplemented with ketoanalogues (Group A)
Trial: 10511331
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein restriction diet (0.65 g/kg/day) (Group B)
Trial: 6240785
Drug: Thiamphenicol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamphenicol (2.5 g perorally)
Trial: 22832068
Drug: Fusion model
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fusion model (combination of ERP and power features)
Trial: 10320179
Drug: Clonidine 150
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 150 microg in 15 mL of saline (Group Clonidine)
Trial: 10320179
Drug: Saline 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 15 mL (Group Saline)
Trial: 10320179
Drug: Bupivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 15 mL (Group Bupivacaine)
Trial: 1859757
Drug: Thiopentone and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone and Propofol combination
Trial: 6981173
Drug: Intravenous trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous trimethoprim (TMP) 150 mg/m2 and sulfamethoxazole (SMZ) 750 mg/m2 every 8 hr
Trial: 6981173
Drug: Intravenous trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous trimethoprim (TMP) and sulfamethoxazole (SMZ)
Trial: 31526557
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous vitamin C (1,500 mg every 6 hours)
Trial: 12029403
Drug: Prone Positioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prone Positioning (PP) for 4 hours once daily until patients could sit in an armchair
Trial: 9617717
Drug: Sinemet CR
RxNorm normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sinemet CR (chronic release formulation of levodopa/carbidopa)
Trial: 1779440
Drug: Aqueous acupuncture
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous acupuncture (2 to 5 ml of 20% glucose solution injected into Ho‐Ku (LI 4) and Yang‐Ling‐Chuan (GB 34))
Trial: 30592371
Drug: Everolimus (EVR)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVR) 1.5 mg twice daily starting on day 8
Trial: 28585903
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg twice daily for 30 days
Trial: 28585903
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg daily for 30 days
Trial: 26206864
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus higher-intensity, progressive aerobic exercise (S+PAE)
Trial: 26206864
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus lower-intensity, non-progressive exercise (S+NPE)
Trial: 18854549
Drug: Two-weekly oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two-weekly oxaliplatin 85 mg/m(2) + continuous intravenous infusion (CIV) of 5‐FU without LV or two‐weekly bolus and CIV 5‐FU + LV (LV5FU2)
Trial: 17407646
Drug: Analogue basal-bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analogue basal-bolus insulin (insulin detemir plus insulin aspart)
Trial: 17407646
Drug: Human basal-bolus
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human basal-bolus insulin (Neutral Protamine Hagedorn plus human soluble insulin)
Trial: 11136280
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg for 2 weeks (Group A)
Trial: 11136280
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg for 2 weeks (Group B)
Trial: 30770244
Drug: Lidocaine/Ketorolac combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/Ketorolac combination (1.5 mg/kg lidocaine and 30 mg ketorolac)
Trial: 30511473
Drug: Lamotrigine extended-release
RxNorm normalized name: Lamotrigine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine extended-release formulation (test group)
Trial: 17467513
Drug: Valsartan (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (40-160 mg per day)
Trial: 17467513
Drug: Control (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (other treatment without angiotensin receptor blockers)
Trial: 15011856
Drug: Injection sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sclerotherapy (diluted adrenalin 1:10,000 plus polidocanol 1%, group B)
Trial: 11724223
Drug: Tramadol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (75 mg)
Trial: 11724223
Drug: APAP (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAP (650 mg)
Trial: 8484506
Drug: Intranasal meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal meperidine (6 sprays, 27 mg)
Trial: 8484506
Drug: Intravenous meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine (6 mL, 27 mg)
Trial: 8484506
Drug: Intranasal NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal NaCl 0.9% (6 sprays)
Trial: 8484506
Drug: Intravenous NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous NaCl 0.9% (6 mL)
Trial: 2892582
Drug: Bevantolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol (200 mg) + Hydrochlorothiazide (25 mg)
Trial: 26404844
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin (OT) administration (40 IU)
Trial: 24394704
Drug: Flavanol-rich soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-rich soluble cocoa product (7.5 g per serving, 2 servings per day, providing 45.3 mg flavanols per day)
Trial: 22426371
Drug: MF59-adjuvanted trivalent
RxNorm normalized name: Influenza, adjuvanted, trivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted trivalent influenza subunit vaccine Fluad (®)
Trial: 22426371
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of MF59 (®)
Trial: 16640103
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indinavir (IDV) 800 mg three times daily with zidovudine (AZT)/lamivudine (3TC) twice daily
Trial: 16640103
Drug: Indinavir/ritonavir (IDV/RTV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir/ritonavir (IDV/RTV) 800/100 mg twice daily with zidovudine (AZT)/lamivudine (3TC) twice daily
Trial: 12894981
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of the discriminant with the level of suspicion values of the radiologist
Trial: 8796408
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of muscle relaxant
Trial: 1636580
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (1200 mg/day for 14 days)
Trial: 1636580
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (2400 mg/day for 7 days)
Trial: 4032694
Drug: Ordinary dose
RxNorm normalized name: ordinary salt combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary dose fentanyl (15 mcg/kg)
Trial: 4032694
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose fentanyl (37 mcg/kg)
Trial: 30408115
Drug: CAB LA
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAB LA 600 mg IM every 8 weeks
Trial: 30408115
Drug: CAB LA
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAB LA 800 mg IM every 12 weeks
Trial: 30408115
Drug: CAB LA
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAB LA (both doses)
Trial: 26537369
Drug: Minocycline hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline hydrochloride ointment (MHO)
Trial: 26537369
Drug: Erythromycin eye
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin eye ointment (EEO)
Trial: 22333852
Drug: Topical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prostaglandin analogues (PGAs) administered over 24 weeks
Trial: 20833738
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at a target dose of 2 g/day
Trial: 20833738
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) at a target dose of 2 mg/kg/day
Trial: 16338269
Drug: Multiple antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple antihypertensive agents
Trial: 11889016
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide pulse therapy
Trial: 10567782
Drug: gemifloxacin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemifloxacin administration
Trial: 220733
Drug: Adriamycin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (40 mg/m2) given every 4 weeks
Trial: 220733
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment group (15 patients)
Trial: 31675184
Drug: Robotic-assisted passive
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic-assisted passive movement treatment
Trial: 22042958
Drug: paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel plus sequential trastuzumab weekly for 52 weeks (arm B)
Trial: 22042958
Drug: paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel plus concurrent trastuzumab for 12 weeks followed by trastuzumab for 40 weeks (arm C)
Trial: 22042958
Drug: doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by paclitaxel weekly for 12 weeks (arm A)
Trial: 17005077
Drug: Nourishing yin
RxNorm normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nourishing yin and Unblocking meridians Recipe (NUR) combined with opioid analgesics
Trial: 18590407
Drug: Opioid analgesics
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesics alone
Trial: 11549098
Drug: Ezetimibe (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (daily doses ranging from 0.25 to 10 mg for 12 weeks)
Trial: 31628524
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus first-line chemotherapy (paclitaxel plus carboplatin)
Trial: 31628524
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (paclitaxel plus carboplatin)
Trial: 22011016
Drug: Real rTMS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real rTMS (high-frequency over left dorsolateral prefrontal cortex for 25 minutes) plus individualized speech therapy
Trial: 22011016
Drug: Placebo rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rTMS plus individualized speech therapy
Trial: 18611959
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of oral amoxycillin
Trial: 16481188
Drug: Intrapleural intercostal
RxNorm normalized name: INTRAPLEURAL MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural intercostal nerve block (IINB) with 20 ml (7.5 mg/ml) ropivacain injection at the dose of 4 ml for each space from the 4th to the 8th space.
Trial: 10690696
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation for malnourished residents (score <17)
Trial: 10690696
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation for residents at risk of malnutrition (score 17-23.5)
Trial: 10690696
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral supplementation for residents with score 24
Trial: 9339691
Drug: tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone 200 mg tid
Trial: 9339691
Drug: tolcapone 100
RxNorm normalized name: tolcapone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone 100 mg tid
Trial: 8274414
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy for 1 month (n = 12)
Trial: 8274414
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy for 24 hours (n = 7)
Trial: 3011048
Drug: Active treatments
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatments (oral and intravenous trimazosin)
Trial: 27874935
Drug: BLIS K12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLIS K12 (Bactoblis) daily for 6 months
Trial: 26145468
Drug: Salt treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt treatment for 17 days along with dental sanitation and treatment of gingivitis
Trial: 19020153
Drug: Intranasal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal morphine 7.5 mg
Trial: 19020153
Drug: Intranasal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal morphine 15 mg
Trial: 19020153
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 7.5 mg
Trial: 19020153
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine 60 mg
Trial: 16877482
Drug: Ciclosporin A
RxNorm normalized name: Ciclosporin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin A to tacrolimus conversion (group A, target tacrolimus trough level 6-8 ng/ml)
Trial: 16877482
Drug: Ciclosporin A
RxNorm normalized name: Ciclosporin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin A minimization (group B, target CsA trough level 80-100 ng/ml)
Trial: 10385545
Drug: Cisplatin-based treatment
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based treatment after cytoreductive surgery
Trial: 8630559
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nebulized natural-derived bovine surfactant (Alveofact)
Trial: 28978542
Drug: Whole eggs
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole eggs (18 g protein, 17 g fat)
Trial: 28978542
Drug: Egg whites
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg whites (18 g protein, 0 g fat)
Trial: 1362592
Drug: Antiparkinsonian drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparkinsonian drugs withdrawal
Trial: 3890428
Drug: Hyperbaric oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygenation (HBO) in multiple modality therapy
Trial: 3890428
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment without HBO
Trial: 27770801
Drug: Balance chiropractic
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance chiropractic therapy (BCT)
Trial: 22424834
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (verteporfin 6 mg/m² PDT and ranibizumab 0.5 mg)
Trial: 22424834
Drug: Ranibizumab monotherapy
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab monotherapy (sham infusion [5% dextrose] PDT and ranibizumab 0.5 mg)
Trial: 19996947
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (300 mg loading dose followed by 15 mg/kg/24h for 2 days)
Trial: 18292850
Drug: FPs' perception
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPs' perception of treatment compliance
Trial: 15996628
Drug: Esomeprazole 20mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg, levofloxacin 500 mg and azithromycin 500 mg once-daily (ELAz)
Trial: 15996628
Drug: Esomeprazole 20mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg, clarithromycin 500 mg and amoxycillin 1g twice-daily (ECA)
Trial: 30466191
Drug: Mealtime fast-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mealtime fast-acting insulin aspart
Trial: 30394552
Drug: Transfusion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion with one unit of RBCs at a hemoglobin level of 9.0 g/dL
Trial: 30394552
Drug: Transfusion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion with one unit of RBCs at a hemoglobin level of 7.0 g/dL
Trial: 26577998
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Levofloxacin + Terazosin)
Trial: 26577998
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Levofloxacin, Terazosin, Combination)
Trial: 25247319
Drug: Cytological examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytological examination using a capsule sponge device
Trial: 22539051
Drug: Scalp cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp cooling with 90-min post-infusion cooling time (PICT)
Trial: 16786786
Drug: Methods for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methods for prevention and treatment of postoperative nausea and vomiting (PONV)
Trial: 12730560
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator (rtPA; Actilyse) administered up to 6 hours after stroke
Trial: 10632905
Drug: Presurgical axillary
RxNorm normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical axillary block with 2 mg.kg-1 of 0.25% bupivacaine
Trial: 10632905
Drug: Postsurgical axillary
RxNorm normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postsurgical axillary block with 2 mg.kg-1 of 0.25% bupivacaine
Trial: 8701508
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract GB‐8 at a dose of 120 mg o.d.
Trial: 1953853
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin after four hours of observation
Trial: 1953853
Drug: Intravaginal 3
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal 3 mg PGE2 gel followed by intravenous oxytocin four hours later
Trial: 6602328
Drug: Aspirin 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 4.0 g/day
Trial: 6602328
Drug: Diflunisal 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 1,000 mg/day
Trial: 25079399
Drug: Proximal hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal hygiene treatment (study 1)
Trial: 23866471
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg) given orally at 10:00 pm the night before operation and at 7:00 am on the day of surgery